MedTrace Logo

Study With Intravenous Busulfan And Fludarabine Myeloablative Conditioning Regimen For HLA Identical Sibling Donor HSCT

NCT01683123 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 143

Last updated 2022-03-17

No results posted yet for this study

Summary

Analyze the results of conditioning with once-daily dose intravenous busulfan and fludarabine in patients undergoing HLA identical sibling Allogeneic HSCT for myeloid malignancies.

Conditions

Sponsors & Collaborators

  • Grupo Espanol de trasplantes hematopoyeticos y terapia celular

    lead OTHER

Principal Investigators

  • Javier De la Serna, MD · Grupo Espanol de trasplantes hematopoyeticos y terapia celular

  • Guillermo Sanz, MD · Grupo Espanol de trasplantes hematopoyeticos y terapia celular

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-07-31
Primary Completion
2011-06-30
Completion
2012-10-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01683123 on ClinicalTrials.gov